			Home About us Contact

Confirmed Report (confirmed + report)

Distribution by Scientific Domains

Medical Sciences	40%

Selected Abstracts

Case report of HbC/,0 -thalassemia from India

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, Issue 5 2007
S. KUMAR
Summary This 22-year-old women presented to the ante-natal clinic of this hospital for prenatal screening for , -thalassemia. Cation exchange high performance liquid chromatography (HPLC) using ,Beta Thalassemia Short Program' on Bio-Rad ,Variant' system revealed HbC value of 81.6%. The CBC showed microcytic hypochromic anemia. The HPLC and CBC suggested the possibility of compound heterozygote state for HbC/, -thalassemia. The alkali and acid electrophoresis findings were consistent with the above diagnosis. The DNA analysis confirmed compound heterozygote state for HbC/,0 -thalassemia (Fr 8/9 mutation). The studies on the parents showed that mother was a compound heterozygote for HbDPunjab and HbC while father had , -thalassemia trait. To the best of our knowledge, this is the first confirmed report of HbC from India. The paper discusses the hematological findings in this subject and her mother (a compound heterozygote for HbDPunjab and HbC). [source]

First confirmed report of sugarcane common rust (Puccinia melanocephala) in Ethiopia

PLANT PATHOLOGY, Issue 6 2009
P. L. Kelly
No abstract is available for this article. [source]

Quambalaria species associated with plantation and native eucalypts in Australia

PLANT PATHOLOGY, Issue 4 2008
G. S. Pegg
This study aimed to determine which species of Quambalaria are associated with shoot blight symptoms on Corymbia spp. An additional aim was to determine the presence and impact of quambalaria shoot blight on Eucalyptus species used in plantation development in subtropical and tropical regions of eastern Australia. Surveys identified three Quambalaria spp. ,Q. pitereka, Q. eucalypti and Q. cyanescens, from native and plantation eucalypts, as well as amenity plantings, including the first confirmed report of Q. eucalypti from Eucalyptus plantations in Australia. Symptom descriptions and morphological studies were coupled with phylogenetic studies using ITS rDNA sequence data. Quambalaria pitereka was the causal agent of blight symptoms on species and hybrids in the Corymbia complex. Quambalaria eucalypti was identified from Eucalyptus species and a single Corymbia hybrid. Quambalaria cyanescens was detected from native and plantation Corymbia spp. [source]

First confirmed report of downy mildew caused by Hyaloperonospora parasitica on broccoli in Korea

PLANT PATHOLOGY, Issue 4 2008
S. Y. Hong
No abstract is available for this article. [source]

FEIBA® safety profile in multiple modes of clinical and home-therapy application

HAEMOPHILIA, Issue 2004
H. Luu
Summary., The development of neutralizing antibodies to factor VIII or IX therapeutic concentrates remains the most serious and challenging complication in the management of patients with haemophilia A and B. FEIBA®, Anti-Inhibitor Coagulant Complex, is an activated prothrombin complex concentrate that has been used to treat patients with such complications for almost 30 years. The mechanism of action of FEIBA® has been proposed to involve simultaneous FVIII/FIX inhibitor bypassing action in the common, intrinsic and extrinsic coagulation pathways. FEIBA® is derived from human plasma that undergoes stringent viral screening followed by significant viral inactivation and removal. To date, there have been no confirmed reports of transmission of hepatitis A, B or C, or of human immunodeficiency viruses associated with the use of the current, vapour-heat-treated FEIBA® concentrate. The incidence of thrombotic adverse events recorded in the Baxter pharmacovigilance database for the 10-year postmarket period (1990,99) was approximately 4 : 100 000 infusions of FEIBA®. Almost all documented thrombotic events with FEIBA® occurred with doses that exceeded dosing recommendations, and known risk factors for cardiovascular disease were evident in more than 80% of the patients involved. Overall, clinical data have shown FEIBA® to be safe and well-tolerated for use in a wide variety of clinical settings, including treatment of bleeding episodes, management of surgical procedures, home therapy, long-term prophylaxis, and prophylaxis during immune tolerance induction, when used according to dosing guidelines. [source]